Core Viewpoint - The company, Keyuan Pharmaceutical, anticipates a significant decline in net profit for the year 2025, projecting a decrease of 35% to 55% compared to the previous year, primarily due to increased expenses in various operational areas [1] Summary by Categories Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between 27.20 million and 39.29 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 20.12 million and 29.06 million yuan [1] Expense Increases - The company has increased its efforts in the formulation market, leading to higher sales expenses [1] - Management fees have risen due to payments made for restructuring-related intermediary services [1] - Research and development expenses have increased as the company continues to adhere to its "innovation-driven development" strategy, investing in new product development and improving its R&D management system [1] Other Income and Asset Impairment - There has been a reduction in government subsidies related to daily operational activities, resulting in decreased other income [1] - The company has conducted a comprehensive review of various receivables and assets, leading to an increase in asset impairment losses due to prudent and reasonable accounting judgments [1]
科源制药：2025年全年净利润同比预减35.00%—55.00%